Nearly a doubling of survival time in a disease where gains were once measured in weeks
For decades, pancreatic cancer stood as one of medicine's most humbling frontiers — a disease where the very gene driving nearly every tumor was considered structurally beyond reach. A phase 3 trial published in the New England Journal of Medicine now suggests that wall has been breached: daraxonrasib, by approaching the KRAS mutation indirectly through a molecular chaperone protein, nearly doubled median survival in metastatic patients compared to standard chemotherapy. In a disease where progress has long been measured in weeks, this may mark the beginning of a different kind of conversation.
- Metastatic pancreatic cancer has resisted targeted therapy longer than almost any other major malignancy, leaving patients with few options beyond chemotherapy that offers only months of survival.
- Daraxonrasib cracks a decades-old impasse by binding cyclophilin A rather than KRAS directly — a conceptual workaround that finally makes the 'undruggable' mutation druggable.
- In a 500-patient trial, those receiving daraxonrasib survived a median of 13.2 months versus 6.7 months on chemotherapy, a roughly 60% reduction in mortality risk that stunned the oncology community.
- Patients also reported reduced pain and improved daily functioning, and fewer discontinued treatment due to severe toxicity than those on conventional chemotherapy — a critical advantage in a fragile population.
- FDA approval is anticipated soon, while researchers are already designing combination trials with immunotherapy and other agents to push responses further and outpace emerging resistance.
Pancreatic cancer has long been one of oncology's most unforgiving diagnoses — aggressive, fast-moving, and resistant to the precision therapies that transformed treatment for other cancers. At the center of that resistance sits the KRAS gene, mutated in more than 90 percent of pancreatic tumors, which locks cells into a state of uncontrolled growth. For decades, its smooth molecular surface gave drugs nothing to grip, earning it the label 'undruggable.'
Daraxonrasib found a way around the problem. Rather than targeting KRAS directly, the drug binds to cyclophilin A, a protein that helps fold other proteins into functional shapes. This indirect approach disrupts mutant KRAS signaling without ever confronting the target head-on — an elegant conceptual shift that unlocked what direct assault could not.
A phase 3 trial enrolling roughly 500 patients with metastatic pancreatic cancer who had already received prior treatment showed the drug's impact in stark terms: a median survival of 13.2 months, compared to 6.7 months with standard chemotherapy. In a disease where gains have historically been counted in weeks, a near-doubling of survival time carried enormous weight across the oncology community.
Equally meaningful was what patients experienced beyond the numbers. Pain eased. Daily life became more manageable. Though side effects including rash, mouth sores, and nausea were common, fewer patients abandoned treatment due to severe toxicity than those on conventional chemotherapy — a significant consideration for people already weakened by advanced disease.
Regulatory approval is expected to follow swiftly given the clinical significance of the results. Researchers are already looking ahead to combination strategies — pairing daraxonrasib with immunotherapy and other targeted agents — to extend responses and stay ahead of resistance. For a disease that has long offered little beyond a conversation about months, that horizon is beginning to look different.
Pancreatic cancer has long occupied a grim corner of oncology—aggressive, lethal, and stubbornly resistant to the targeted therapies that have transformed treatment for other malignancies. The disease kills most of those it touches, often before they even know they have it. But a phase 3 clinical trial published in the New England Journal of Medicine suggests that may be about to change. A drug called daraxonrasib has demonstrated something oncologists rarely see in pancreatic cancer: a meaningful extension of life.
The breakthrough centers on a genetic mutation that haunts nearly every pancreatic tumor. The KRAS gene, mutated in more than 90 percent of pancreatic adenocarcinomas, drives uncontrolled cell growth by remaining perpetually switched on. For decades, KRAS was considered untouchable—a molecular target so structurally smooth that conventional drug molecules simply could not grip it. Researchers called it "undruggable," and the label stuck. While scientists cracked the KRAS problem in lung and colorectal cancers, pancreatic tumors remained largely beyond reach.
Daraxonrasib works by sidestepping the problem entirely. Rather than attacking KRAS directly, the drug binds to a cellular protein called cyclophilin A, which helps fold other proteins into their proper shapes. This indirect approach—a conceptual shift in how oncologists think about inaccessible targets—allows the drug to block mutant KRAS activity and shut down the signals that fuel tumor growth. It is an elegant solution to a problem that had resisted direct assault.
The trial enrolled roughly 500 patients with metastatic pancreatic cancer who had already received prior treatment. Those given daraxonrasib lived a median of 13.2 months, compared to 6.7 months for patients treated with standard chemotherapy. That is nearly a doubling of survival time—a 60 percent reduction in the risk of death. In a disease where therapeutic gains have historically been measured in weeks, the magnitude of this benefit reverberated through the oncology community.
Beyond the survival numbers, patients reported something equally important: their quality of life improved. Pain diminished. Symptoms that had dominated their days became more manageable. The most common side effect was a rash, occurring in more than 86 percent of participants, along with mouth sores, diarrhea, nausea, and vomiting. Yet fewer patients stopped treatment due to severe toxicity with daraxonrasib than with conventional chemotherapy—a significant finding for a population already weakened by advanced disease.
The success reflects a broader shift in cancer medicine away from blunt cytotoxic drugs toward precision therapies tailored to a tumor's molecular fingerprint. That strategy has already reshaped treatment for certain lung and colorectal cancers. Now it is reaching into territory that has resisted it for years. Researchers are already planning the next phase: combining daraxonrasib with immunotherapy, chemotherapy, and other targeted agents to see if they can extend responses even further and delay the emergence of drug-resistant tumors.
Regulatory approval appears likely. The FDA and other international agencies are expected to move quickly given the clinical significance of these results. If daraxonrasib reaches patients, it will mark a genuine inflection point for a disease that has offered little hope for so long. For decades, metastatic pancreatic cancer meant a conversation about months, not years. That conversation may finally be changing.
Notable Quotes
Patients reported improved quality of life and reduced symptom burden, particularly pain, compared to conventional chemotherapy— Trial authors
Proteins considered inaccessible can be controlled through indirect mechanisms of molecular modulation— Oncology researchers on the trial's conceptual significance
The Hearth Conversation Another angle on the story
Why did KRAS stay "undruggable" for so long when other cancer genes didn't?
The protein's surface is essentially featureless—smooth in a way that makes it nearly impossible for traditional drug molecules to find a place to bind. It's like trying to grip a ball bearing with your fingers. Other mutations have structural pockets or grooves where drugs can wedge in.
So daraxonrasib doesn't actually touch KRAS at all?
Correct. It binds to cyclophilin A instead, a completely different protein. That binding creates a complex that indirectly shuts down what KRAS is doing. It's a workaround, not a direct hit.
That sounds like it could apply to other "undruggable" targets.
Exactly. This trial is proof that the problem wasn't the target itself—it was our approach to it. If you can't grab something head-on, you find another way into the system.
What happens to patients who develop resistance to daraxonrasib?
That's the open question. The next studies will combine it with other drugs to try to prevent or delay resistance. But we don't yet know what happens when tumors learn to work around it.
How soon could this actually be available to patients?
The FDA could move quickly given these results. Accelerated review is likely. But regulatory approval and actual availability in clinics are two different timelines. Still, we're probably talking months, not years.
For someone with metastatic pancreatic cancer right now, what does this mean?
It means there's finally a real option beyond chemotherapy. Not a cure, but a genuine chance at more time and a better quality of life while you have it. That's not nothing in a disease where the median survival used to be measured in single-digit months.